TLR4 and neoplasm: In this study, we provide for the first time the initial in vivo characterization of the activity and in vitro characterization of possible underlying mechanism(s) contributing to the inhibition of metastatic disease and show that pharmacological grade Immunomax® is acting as a TLR-4 agonist directly activating DCs and significantly enhancing anti-tumor killing capacity of NK cells.